Keeping you up to date with the latest clinical trial information
Acromegaly
 |
Acromegaly—An Update on Clinical Approach and Management
Acromegaly is an uncommon disorder characterized by excess secretion of growth hormone (GH), resulting in the classical growth of bone and soft tissues,multi-system involvement with multiple comorbidities, and heightened risk of premature mortality.
|
 |
Carney complex (CNC)
The Carney complex (CNC) is a dominantly inherited syndrome characterized by spotty skin
pigmentation, endocrine overactivity and myxomas.
|
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
This study will investigate the efficacy of a combination treatment with octreotide acetate and
cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy
Related Articles
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
The purpose of the study is to evaluate the effects of growth hormone (GH) replacement in men and women with a history of acromegaly and who are now growth hormone deficient.
Related Articles
Estrogen Treatment in Acromegalic Women
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
Related Articles
currently marketed femhrt 1 mg/5 mcg) is indicated for the treatment
of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
The company expects to launch the new low-dose Femhrt 0.5 mg/2.5 mcg in the second quarter of 2005.
